Registration Header

live date:Tuesday, November 9, 2021

Duration:60 minutes

Plasma proteomics is increasingly recognized as a fundamental approach to accelerate biomarker discovery and drug development, taking precision medicine to the next level. 

Liquid biopsy, utilizing blood as a less invasive alternative for tissue samples, is becoming more and more prominent in precision medicine. The possibility to analyze blood samples across the species matrix makes mass spectrometry-based proteomics a powerful tool for early-stage, translational, and clinical research. 

The integration of proteomics into the research pipeline helps to accelerate and de-risk drug development by bridging insights from the genotype and the phenotype to decode the complexity of disease pathways. Biognosys’ new and improved plasma biomarker discovery solution takes an unbiased and hypothesis-free approach to analyze the proteome beyond the expected. Starting from the complete proteome, the workflow identifies 3,000 of the most relevant proteins and an unlimited number of proteoforms in plasma and serum samples.

Prof. Manuel Mayr from King’s College London, discussed the importance of mass spectrometry-based plasma proteomics in cardiovascular and Covid-19 research. Marco Tognetti, PhD from Biognosys, demonstrated the application of Biognosys’ optimized plasma workflow in a pan-cancer study focused on identifying biomarker candidates from tissue leakage. Finally, Kanna Palaniappan, PhD from Freenome, shared perspectives on the value of unbiased proteomics for intelligent data analysis in early cancer detection. The webinar concluded with a panel discussion, chaired by Biognosys CEO and co-founder Oliver Rinner, PhD.

Key learning objectives:

  • The importance of the plasma proteome in research and clinics
  • Advantages of mass spectrometry methods to analyze the plasma proteome
  • The application of Biognosys’ innovative plasma proteomics workflow in clinical research

Click the button below to access the login portal:



Manuel Mayr, MD, PhD

Professor of Cardiovascular Proteomics

King's College London

Manuel Mayr qualified in Medicine from the University of Innsbruck (Austria) in 1999. He then moved to London to undertake a PhD. Upon completion of his PhD, he achieved promotion to Professor in 2011. He has been awarded a prestigious British Heart Foundation Personal Chair in 2017. His academic achievements have been recognised by the inaugural Michael Davies Early Career Award of the British Cardiovascular Society (2007), the inaugural Bernard and Joan Marshall Research Excellence Prize of the British Society for Cardiovascular Research (2010), and the Outstanding Achievement Award by the European Society of Cardiology Council for Basic Cardiovascular Science (2013).

Marco Tognetti, PhD

Principal Scientist


Marco Tognetti, Ph.D., is a principal scientist R&D at Biognosys. He is responsible for developing novel sample processing protocols, such as next-generation plasma depletion and immuno-peptide enrichment, and the improvement and automation of current ones. Marco obtained his BSc, MSc, and Ph.D. from ETH Zurich. Before joining Biognosys in 2020, his research at ETH Zurich and the University of Zurich brought him to integrate multi-omics approaches to improve drug response prediction in breast cancer.

Oliver Rinner, PhD



Founder, CEO, Board Director. Oliver was co-founder of Biognosys in 2008 and is leading the company as CEO, starting as a spin-off from ETH Zurich to a market-leading inventor and provider of proteomics technology that Biognosys is today. A psychologist and biochemist by training, Oliver joined the group of proteomics pioneer Ruedi Aebersold at the ETH in 2005, where he worked on the development of technologies for targeted and structural proteomics and contributed to the seminal papers and patents in the Aebersold group that laid the foundation of the next-generation proteomics. Oliver is also a member of the Board of Directors of Biognosys.

Kanna Palaniappan, PhD

Staff Scientist


Kanna Palaniappan, Ph.D., is a staff scientist at Freenome, where he leads a research program focused on identifying protein biomarkers for early cancer detection, and translating those markers into clinical products. Kanna obtained his Ph.D. from UC Berkeley, where he developed new tools for chemically-directly glycoproteomics and for MRI-based molecular imaging, in the laboratories of Professor's Carolyn Bertozzi and Matthew Francis. Subsequently, he was an early member of the Google Life Sciences team and a founding member of Verily Life Sciences, where he worked on projects spanning nanotechnology to systems biology. Kanna joined Freenome in 2018 to build their protein research platform.
First Name
Last Name
Email Address
Job Title
Are you considering incorporating proteomics into your research?
Yes, I already have a preferred proteomics platform
Yes, I am currently evaluating proteomics platforms
Maybe, I am exploring options
No interest at the moment
What are your application areas of interest:
Biofluid Biomarker Discovery
Tissue Biomarker Proteomics
Mechanism of Action Studies
Phospho-profiling Studies

By completing and submitting this registration, the personal and professional information you submit herein will be provided to Biognosys AG and its affiliates for processing in accordance with the terms of its Privacy Policy.

© 2021 Notified. All rights reserved.